RxDoctor Payments Data

Jodie Labowitz, MD

Gastroenterology · Glendale, AZNPI 1922074012

Payments from drug & device makers

$4,366in general payments, 2019–2025

Across 221 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$839
  • AbbVie$680
  • Takeda Pharmaceuticals U.S.A., Inc.$555
  • Pfizer$417
  • Ardelyx, Inc.$235
  • Sanofi$234
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,349100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,366 in reported general payments places this provider in the 50th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$68,896
Medicare patients
311
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$555,134
LinzessLinaclotide52$37,323
Alosetron Hcl17$34,338
IbsrelaTenapanor Hcl14$23,636
Mesalamine38$22,524
Budesonide EcBudesonide15$12,849
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates76$5,403
Balsalazide Disodium27$4,660
Omeprazole258$3,569
Mesalamine ErMesalamine12$3,150
Pantoprazole Sodium159$2,061
Mercaptopurine17$2,040
Famotidine115$1,572
Sucralfate48$1,569
Budesonide DrBudesonide16$1,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$145$555,13419 claims
AbbVieLinzess$680$37,32352 claims
Ardelyx, Inc.Ibsrela$235$23,63614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →